The use of a newly-developed mosquito trap incorporating human odour has resulted in a 70% decline in the population of the most significant malaria mosquito on the Kenyan island of Rusinga. After the introduction of the odour-baited traps on the island the proportion of people with malaria was 30% lower among those living in houses with a trap compared to people living in houses who were yet to receive a trap. The study was published today in The Lancet, a leading scientific journal. Prof. Willem Takken led the three-year study with Wageningen University & Research scientists and researchers from the Kenyan International Centre of Insect Physiology and Ecology (ICIPE) and the Swiss Tropical and Public Health Institute (Swiss TPH).
Zika and dengue fever
The odour-baited trap may also offer a solution to diseases like dengue fever and the Zika virus. Aedes aegypti (the yellow fever mosquito), is a vector for these viruses. This mosquito is attracted to the same humanised scent that attracts malaria mosquitoes. Zika and dengue fever could therefore be combated with the odour-baited traps.
Better living conditions
The success of the new approach is the combination of the odour-baited trap with mosquito nets, anti-malaria drugs, and a solid social strategy. The odour-baited traps need electricity to operate, but there is no central electricity supply on Rusinga, an island in Lake Victoria. Solar panels were installed on the roofs of homes. These not only provided electricity for the mosquito traps but also provided the homes with power for light and to charge a mobile phone. The use of solar energy to control malaria gave rise to the project name: SolarMal. Great efforts were also made in relation to education about malaria and actively engaging the inhabitants of Rusinga in the project. Thanks to this combined approach, all 25,000 inhabitants of Rusinga participated in the study. When the odour-baited traps are used, the use of insecticides to combat the mosquito population can be minimised, thus avoiding any harmful side effects of such products. The Wageningen anti-malaria approach therefore has positive effects in reducing the spread of malaria as well as positive effects on the living conditions of the population.
Text continues below the video
- Helaas, uw cookie-instellingen zijn zodanig dat de Video niet getoond kan worden - pas uw permissie voor cookies aan
Malaria: a major cause of death and an economic problem
Every minute, a child dies of malaria. This disease costs Africa twelve billion dollars a year in health-care costs and lost productivity, particularly in the agricultural sector. Fighting malaria without using insecticides is vital to world food production. “The effect of the disease on agricultural production is hugely underestimated,” says Willem Takken. “As children with malaria need access to hospital care, their parents cannot work on the land and as a result food production rates decline. If those parents themselves also suffer from malaria infections four or five times a year, they are also not able to work for around six weeks. In such cases, extra labour needs to be brought in or the crop will be lost. An African household loses 10% of its annual incomes through malaria. It is for good reason that reducing the prevalence of malaria was included in the ten millennium development goals formulated by the UN.”
The World Health Organization (WHO) is aiming to eradicate malaria by 2030. To this end, investments are being made in the development of vaccines against the parasite and in combating the vectors of the parasite: the mosquitoes. The odour-baited trap - named ‘the Suna trap’ - represents an effective and safe solution in the fight against the mosquito.
The effect of mass mosquito trapping on malaria transmission and disease burden (SolarMal): a stepped-wedge cluster-randomised trial. Tobias Homan, Alexandra Hiscox, Collins K Mweresa, Daniel Masiga, Wolfgang R Mukabana, Prisca Oria, Nicolas Maire, Aurelio Di Pasquale, Mariabeth Silkey, Jane Alaii, Teun Bousema, Cees Leeuwis, Thomas A Smith, Willem Takken. The Lancet on line publicatie, 9 augustus 2016.